Teva-Pregabalin 150 mg Capsules Recall Due to Sertraline Contamination
Areazine synthesizes this Health Canada recall directly from Health Canada's official public data feed. See our methodology for full source attribution and refresh cadence.
Health Canada has recalled two lots of Teva-Pregabalin 150 mg capsules due to cross-contamination with sertraline, posing risk of serious allergic reactions.
What this Health Canada recall tells you, and what most readers miss
This notice was issued by Health Canada on August 15, 2026 and geographically references Canada. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Product & Food Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, health-canada, medication.
What Happened
Teva Canada Ltd. is recalling two lots of Teva-Pregabalin 150 mg capsules after routine testing identified that some capsules may be contaminated with the drug sertraline. Patients with a hypersensitivity or allergy to sertraline could experience side effects or have a serious allergic reaction, including an anaphylactic reaction, even at a low exposure.
Which Products Are Affected
- Teva-Pregabalin 150 mg capsules (DIN 02361205)
- Lot numbers: 100070495 and 100068913
- Expiry: July 31, 2027 Products from the recalled lots were first sold in Canada in September 2025.
What You Should Do
If you experience a serious allergic reaction (anaphylaxis), stop taking the affected product and seek immediate medical help by calling 9-1-1. Otherwise, do not stop taking your pregabalin medication without first speaking with your healthcare professional or pharmacist. Return the product to the pharmacy where it was purchased as soon as possible for a replacement or alternative supply. Contact Teva Canada Customer Care by calling toll-free at 1-800-268-4129 or by email at customer.service@tevacanada.com if you have questions.
Why This Matters
Anaphylactic reaction symptoms can be fatal and may include shortness of breath, swelling, fainting, or widespread rash.
Source
Original source: Health Canada Official Notice ↗
Related Product & Food Recalls
All Product & Food Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this Health Canada recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,451 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to August 15, 2026.
Frequently Asked Questions
Common questions about this Health Canada recall.